Scientists from the IRB Barcelona IRB Barcelona Institute formed a Diffinvex Information Processing Platform that can define genes that help “move away from chemotherapy of cancer cells. Research Results published In Nature Communications (Natcom).
The platform was trained with 11 thousand genomic cancer and healthy tissue sample. Algorithms covered about 30 different cell species. Diffinvex showed the ability to correctly identify mutations that contribute to drug stability and determine genes in the development of resistance to treatment. Among these genes were PIK3CA, SMAD4 and NGK11 – famous “drivers” of tumor growth.
Diffinvex technique is based on the comparison of the frequencies of mutations in DNA coding areas with non -adjacent regions. This approach allows you to more accurately evaluate the effect of genetic variability without neglecting.
The analysis also showed that some mutations, including changes in the ARID1A gene, may occur during the normal aging process and that they are not always related to the development of tumors. This questions their roles as real oncogenic provocateurs and can affect early diagnostic strategies.
According to scientists, the discovery of the “universal” development of resistant cancer can contribute to the creation of more accurate drug combinations. For example, a combination of traditional chemotherapy with signal inhibitors activated by PIK3CA or NGO11 genes may delay recurrence.
Previously found A gene that protects against the form of hereditary dementia.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.